GlassScriptPhysician profile
Qing Ni
NPI 1295765311
$42,081.82
in general payments reported to CMS, 2019-2025
74 companies · $3,467 in 2025
The $3,467 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,360 · 2020: $2,370 · 2021: $16K · 2022: $9,964 · 2023: $3,736 · 2024: $4,208 · 2025: $3,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,150.56 |
| Education | $260.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $12,051.68 | 2020-2021 | |
| Sk Life Science, INC. | $5,559.48 | 2020-2025 | |
| Abbvie INC. | $3,567.77 | 2021-2025 | |
| Ucb, INC. | $1,784.91 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Upsher-Smith Laboratories LLC | $1,004.05 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $892.80 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Jazz Pharmaceuticals INC. | $785.06 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $747.94 | 2019-2025 | |
| Neurelis, INC. | $721.50 | 2021-2025 | Valtoco |
| Alexion Pharmaceuticals, INC. | $720.06 | 2019-2025 | Ultomiris, Soliris |
| Pfizer INC. | $691.66 | 2021-2025 | |
| Lilly USA, LLC | $666.64 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Scilex Pharmaceuticals INC. | $638.36 | 2022-2025 | Ztlido |
| Sunovion Pharmaceuticals INC. | $626.12 | 2019-2022 | |
| Mdd US Operations, LLC | $597.00 | 2019-2025 | Gocovri, Gocovri, Qelbree |
Show all 74 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Qing Ni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.